Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD.

Vijayakumar S, Dang S, Marinkovich MP, Lazarova Z, Yoder B, Torres VE, Wallace DP.

Am J Physiol Renal Physiol. 2014 Mar 15;306(6):F640-54. doi: 10.1152/ajprenal.00104.2013. Epub 2013 Dec 26.

2.

Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.

Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP.

J Am Soc Nephrol. 2006 Jan;17(1):178-87. Epub 2005 Nov 30.

3.

Distribution of alpha-integrin subunits in fetal polycystic kidney diseases.

Daïkha-Dahmane F, Narcy F, Dommergues M, Lacoste M, Beziau A, Gubler MC.

Pediatr Nephrol. 1997 Jun;11(3):267-73.

PMID:
9203171
4.

Macrophages promote polycystic kidney disease progression.

Swenson-Fields KI, Vivian CJ, Salah SM, Peda JD, Davis BM, van Rooijen N, Wallace DP, Fields TA.

Kidney Int. 2013 May;83(5):855-64. doi: 10.1038/ki.2012.446. Epub 2013 Feb 20.

5.

Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.

Togawa H, Nakanishi K, Mukaiyama H, Hama T, Shima Y, Sako M, Miyajima M, Nozu K, Nishii K, Nagao S, Takahashi H, Iijima K, Yoshikawa N.

Am J Physiol Renal Physiol. 2011 Feb;300(2):F511-20. doi: 10.1152/ajprenal.00038.2010. Epub 2010 Nov 17.

PMID:
21084407
6.

Tissue culture correlational study of genetic cholangiopathy of autosomal recessive polycystic kidney disease.

Nakanuma Y, Sato Y, Harada K.

Methods Mol Biol. 2013;945:303-18. doi: 10.1007/978-1-62703-125-7_18.

PMID:
23097114
7.

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.

Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ.

Kidney Int. 2004 Sep;66(3):964-73.

8.

The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.

Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE.

Kidney Int. 2001 Jan;59(1):126-36.

9.

Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

Gradilone SA, Masyuk TV, Huang BQ, Banales JM, Lehmann GL, Radtke BN, Stroope A, Masyuk AI, Splinter PL, LaRusso NF.

Gastroenterology. 2010 Jul;139(1):304-14.e2. doi: 10.1053/j.gastro.2010.04.010. Epub 2010 Apr 14.

10.

Cux1 promotes cell proliferation and polycystic kidney disease progression in an ADPKD mouse model.

Porath B, Livingston S, Andres EL, Petrie AM, Wright JC, Woo AE, Carlton CG, Baybutt R, Vanden Heuvel GB.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F1050-F1059. doi: 10.1152/ajprenal.00380.2016. Epub 2017 Jul 12.

PMID:
28701314
11.

Laminin 5 regulates polycystic kidney cell proliferation and cyst formation.

Joly D, Berissi S, Bertrand A, Strehl L, Patey N, Knebelmann B.

J Biol Chem. 2006 Sep 29;281(39):29181-9. Epub 2006 Jul 26.

12.

Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.

Wang X, Harris PC, Somlo S, Batlle D, Torres VE.

Nephrol Dial Transplant. 2009 Feb;24(2):526-34. doi: 10.1093/ndt/gfn527. Epub 2008 Sep 30.

13.

Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys.

Hu B, He X, Li A, Qiu Q, Li C, Liang D, Zhao P, Ma J, Coffey RJ, Zhan Q, Wu G.

Exp Cell Res. 2011 Jan 15;317(2):173-87. doi: 10.1016/j.yexcr.2010.09.012. Epub 2010 Sep 25.

PMID:
20875407
14.

Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease.

Stayner C, Iglesias DM, Goodyer PR, Ellis L, Germino G, Zhou J, Eccles MR.

Hum Mol Genet. 2006 Dec 15;15(24):3520-8. Epub 2006 Nov 2. Erratum in: Hum Mol Genet. 2009 Apr 15;18(8):1543.

PMID:
17082250
15.

Polycystic kidney disease: etiology, pathogenesis, and treatment.

Martinez JR, Grantham JJ.

Dis Mon. 1995 Nov;41(11):693-765. Review.

PMID:
7587886
16.

Proliferative activity of cyst epithelium in human renal cystic diseases.

Nadasdy T, Laszik Z, Lajoie G, Blick KE, Wheeler DE, Silva FG.

J Am Soc Nephrol. 1995 Jan;5(7):1462-8.

17.

Altered Hippo signalling in polycystic kidney disease.

Happé H, van der Wal AM, Leonhard WN, Kunnen SJ, Breuning MH, de Heer E, Peters DJ.

J Pathol. 2011 May;224(1):133-42. doi: 10.1002/path.2856. Epub 2011 Mar 7.

PMID:
21381034
18.

Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations.

Freedman BS, Lam AQ, Sundsbak JL, Iatrino R, Su X, Koon SJ, Wu M, Daheron L, Harris PC, Zhou J, Bonventre JV.

J Am Soc Nephrol. 2013 Oct;24(10):1571-86. doi: 10.1681/ASN.2012111089. Epub 2013 Sep 5.

19.

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF.

Gastroenterology. 2007 Mar;132(3):1104-16. Epub 2006 Dec 20.

PMID:
17383431
20.

Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.

Park F, Sweeney WE Jr, Jia G, Akbulut T, Mueller B, Falck JR, Birudaraju S, Roman RJ, Avner ED.

Am J Physiol Renal Physiol. 2009 Mar;296(3):F575-82. doi: 10.1152/ajprenal.90705.2008. Epub 2009 Jan 7. Erratum in: Am J Physiol Renal Physiol. 2009 Oct;297(4):F1135.

Supplemental Content

Support Center